Unlock instant, AI-driven research and patent intelligence for your innovation.

Application of detection of aspartate aminotransferase and lactate dehydrogenase in early evaluation of clinical efficacy of anti-tumor interventions

An anti-tumor and anti-tumor technology, applied in the direction of microbial determination/inspection, measuring devices, biochemical equipment and methods, etc., can solve problems such as ineffectiveness and waste of treatment opportunities

Active Publication Date: 2016-09-07
BEIJING SUNBIO BIOTECH
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, most cancer patients are actually spending a lot of money, enduring huge drug side effects, wasting precious treatment opportunities, and receiving ineffective treatments

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of detection of aspartate aminotransferase and lactate dehydrogenase in early evaluation of clinical efficacy of anti-tumor interventions
  • Application of detection of aspartate aminotransferase and lactate dehydrogenase in early evaluation of clinical efficacy of anti-tumor interventions
  • Application of detection of aspartate aminotransferase and lactate dehydrogenase in early evaluation of clinical efficacy of anti-tumor interventions

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] Example 1 Elevated serum AST and LDH levels can predict the efficacy of recombinant allosteric human tumor necrosis factor-related apoptosis-inducing ligand in the treatment of multiple myeloma patients

[0037] 1 Inclusion criteria

[0038] 1.1 Meet the diagnostic criteria of MM, MM that has relapsed and progressed after failure or remission of first-line standard chemotherapy;

[0039] 1.2 Age ≥ 18 years old;

[0040] 1.3 Physical condition score ≥ 60;

[0041] 1.4 Expected survival period ≥ three months;

[0042] 1.5 Have not received chemotherapy, radiotherapy, targeted and anti-angiogenic drugs, interferon therapy and other research drugs within two weeks;

[0043] 1.6 No obvious disturbance of major organ function, the following laboratory indicators must meet the following requirements:

[0044] Blood: white blood cells ≥ 2.0×10 9 / L, neutrophils≥1.0×10 9 / L, platelet count ≥30×10 9 / L, hemoglobin ≥ 60g / L.

[0045] Liver function: serum total bilirubin, A...

Embodiment 2

[0137] Example 2 Elevated serum AST and LDH levels can predict the effectiveness of CPT combined with thalidomide in the treatment of patients with multiple myeloma

[0138] 1 Inclusion criteria

[0139] (1) Meet the diagnostic criteria for MM;

[0140] (2) Patient conditions: MM patients who have relapsed after at least two courses of first-line chemotherapy or have disease progression and ineffectiveness after the latest treatment (at least 2 courses), and at least the latest (within three months) treatment The regimen includes thalidomide (Thal for short) or maintenance therapy with thalidomide (the dosage of thalidomide is not less than 100mg / d);

[0141] (3) Age ≥ 18 years old;

[0142] (4) Physical condition score ≥ 60;

[0143] (5) Expected survival period ≥ three months;

[0144] (6) Except for thalidomide, they have not received chemotherapy or radiotherapy within four weeks, and the washout period has passed.

[0145] (7) No obvious impairment of major organ fun...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Sensitivityaaaaaaaaaa
Sensitivityaaaaaaaaaa
Login to View More

Abstract

The invention discloses a method for early evaluation of the clinical curative effect of anti-tumor intervention measures, which comprises detecting the content of tumor damage biomarkers in the patient's blood after a tumor patient has received at least one anti-tumor intervention measure To evaluate the efficacy of this anti-tumor intervention. The tumor injury biomarker is selected from alanine aminotransferase (ALT), aspartate aminotransferase (AST) and lactate dehydrogenase (LDH), and the tumor is a hematological tumor.

Description

technical field [0001] The present invention relates to a method for early assessment of the efficacy of anti-tumor interventions, in particular, a method for predicting the efficacy of anti-tumor interventions by detecting the level changes of tumor damage biomarkers before and after anti-tumor interventions. Background technique [0002] Up to 7 million people worldwide die from cancer every year. Survival rates for patients with common malignancies have been poor, especially for those whose cancer is not diagnosed until an advanced stage. For example, less than 10% of patients with metastatic colon cancer and about 5% of patients with pancreatic cancer can survive for 5 years or more. In fact, at present, the diagnosis and treatment of tumors still adopt the "non-discriminatory treatment" method, that is, the same method is adopted for all patients - diagnosis is made according to tumor type and stage, and patients are treated without considering the biological character...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12Q1/52C12Q1/32
CPCG01N33/57484G01N2333/904G01N2333/91188G01N2800/52G01N33/5091
Inventor 杨世方崔俊生韦鹏郑向君朱冰
Owner BEIJING SUNBIO BIOTECH